Drug Combo Proves Powerful Against Lung Cancer Lockport NY

A two-drug combination treatment in Lockport proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Meghan Higman
(716) 878-7123
219 Bryant Street
Buffalo, NY
STEVEN AMBRUSKO, MD
(412) 878-7349
219 Bryant Street
Buffalo, NY
Amy Papalia Early, MD
716-630-1029
295 Essjay Rd
Buffalo, NY
Philip L Mc Carthy Jr, MD
716-845-8707
Buffalo, NY
Harold O Douglass, MD
72 Andover Ln
Williamsville, NY
Lorna FitzPatrick
(716) 878-7349
219 Bryant Street
Buffalo, NY
Minsoo Kang
(716) 250-2000
3980 Sheridan Dr
Amherst, NY
DEBORAH FAROLINO, MD
(716) 834-9200
3495 Bailey Avenue
Buffalo, NY
Philip L Mc Carthy, MD
716-845-8707
Buffalo, NY
Edward S Henderson, MD
716-834-9200 x3649
3495 Bradley Blvd
Buffalo, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Hormone Therapy for Breast Cancer Lockport NY
Breast tenderness in women taking estrogen/progestin hormone replacement therapy could signal increased chances of developing breast cancer, a new study says. Women taking estrogen plus progestin who reported developing breast tenderness after starting the hormone therapy were 48 percent more likely to develop invasive breast cancer than women on hormone therapy who did not experience breast tenderness.
- Exercise for Breast Cancer Survival Lockport NY
- Delayed Prostate Cancer Therapy Lockport NY
- Genetic Clues for Skin Cancer Therapies Lockport NY
- Fungal Infection Treatments Lockport NY
- Hormone Therapy for Lung Cancer Lockport NY
- Exercise for Prostate Cancer Lockport NY
- Risks for Childhood Cancer Survivors Lockport NY
- Side Effect Of Chemotherapy Drugs Lockport NY